Neuropsychiatric Disorders And Treatment Market Research Report- Global Forecast To 2027

Neuropsychiatric Disorders And Treatment Market Research Report, By Disorders (Degenerative Diseases, Neurotic Disorders, Psychosis And Others), By Treatments (Shock Treatment, Drug Treatment, Others) By End Users (Hospitals, Clinics, Research Centers And Others) - Forecast Till 2023

ID: MRFR/Pharma/0773-HCR | February 2021 | Region: Global | 80 pages

Neuropsychiatric Disorders and Treatment Market Scenario:


Neuropsychiatric is the mental disorder occur due to disturbance in the function of cerebral system. Mania and hallucination are some of the major neuropsychiatric diseases. Neuropsychiatric diseases occur at any age but the paediatric neuropsychiatry is getting a huge demand due to increasing number of infants, children and adolescents suffering from neuropsychiatric diseases. Increasing prevalence of different neuropsychiatric diseases across the globe is the major driving factor for the growth of the market. While long term treatment and lack of clinical trial data for neuropsychiatric diseases may hamper the growth of the market.


Neuropsychiatric Disorders and Treatment Market is expected to grow at a CAGR of 6.2% during forecasted period.


Study Objectives neuropsychiatric disorders and treatment market



  • Detail market analysis of neuropsychiatric disorders and treatment market with region and competitive analysis.

  • Detail analysis of parent market and different drivers and restraints affecting the growth of the market.

  • Detail Information about the present and forecasted market with its key players that influences the market on global scale.

  • Analysis of the market of the different factors like- price analysis, supply chain analysis, porters five force analysis etc.

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the neuropsychiatric disorders and treatment market.

  • Detail information on the possible segments and sub segments of the market. And regional analysis of the market- North America, Europe, Asia Pacific and Middle East and Africa.

  • Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped 


Key Players for neuropsychiatric disorders and treatment market

Astrazeneca (UK), GlaxoSmithKline (UK), Universal Health Services Inc. (US), Biogen (US), Boehringer Ingelheim GmbH (Germany), Eli Lilly (US), Bristol-Meyer Squibb (US), Johnson & Johnson (US), Pfizer (US), Wyeth (US), Otsuka Holdings Co. Ltd (Japan), Astellas Pharma Inc. (Japan)


Segmentation


Neuropsychiatric Disorders and Treatment Market is segmented on the basis of disorders into degenerative diseases, neurotic disorders, psychosis and others. On the basis of treatments it is segmented as shock treatment, drug treatment, others and on the basis of end users it is hospitals, clinics, research centres and others


Figure 1- Neuropsychiatric disorders and treatment market share, by treatment Neuropsychiatric Disorders Treatment Market

Regional Analysis

On regional basis, North America commands the largest share of neuropsychiatric disorders and treatment market. Increasing prevalence of neuropsychiatric disorders and governmental support for the research and development of the medicines in this area are the major driving factor for the growth of the market in North America. Europe commands the second largest market followed by Asia Pacific. Asia Pacific is expected to grow at a fastest rate due to rapid development of the healthcare sector in this regions.


 


Market Assessment Neuropsychiatric Disorders Treatment Market-


Intended Audience



  • Research and Development (R&D) Companies

  • Government and Independent Research Laboratories

  • Government and Independent Regulatory Authorities

  • Contract Research Organizations (CROs)

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities 


The report for neuropsychiatric disorders and treatment market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.2% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Disorders, Treatments and End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Astrazeneca (UK), GlaxoSmithKline (UK), Universal Health Services Inc. (US), Biogen (US), Boehringer Ingelheim GmbH (Germany), Eli Lilly (US), Bristol-Meyer Squibb (US), Johnson & Johnson (US), Pfizer (US), Wyeth (US), Otsuka Holdings Co. Ltd (Japan), Astellas Pharma Inc. (Japan)
  Key Market Opportunities   Increasing number of infants, children and adolescents suffering from neuropsychiatric diseases.
  Key Market Drivers   Increasing prevalence of different neuropsychiatric diseases across the globe


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


The global Neuropsychiatric Disorders and Treatment Market would grow with a 6.2% CAGR during the forecast period of 2019-2025.

North America would dominate the global Neuropsychiatric Disorders and Treatment Market.

The market has players like GlaxoSmithKline (UK), AstraZeneca (UK), Boehringer Ingelheim GmbH (Germany), Universal Health Services Inc. (US), Biogen (US), Bristol-Meyer Squibb (US), Johnson & Johnson (US), Otsuka Holdings Co. Ltd (Japan), Eli Lilly (US), Wyeth (US), Pfizer (US), Astellas Pharma Inc. (Japan), and others.

The Neuropsychiatric Disorders and Treatment Market types are drug treatment, shock treatment, and others.

TABLE OF CONTENTS

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY DISORDERS

5.1 DEGENERATIVE DISEASES

5.2 NEUROTIC DISORDERS

5.3 PSYCHOSIS

5.4 OTHERS

6. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY TREATMENT

6.1 SHOCK TREATMENT

6.2 DRUG TREATMENT

6.3 OTHERS

7. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY END USER

7.1 HOSPITALS

7.2 CLINICS

7.3 RESEARCH CENTRES

7.4 OTHERS

8. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY REGION

8.1 INTRODUCTION

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 WESTERN EUROPE

8.3.1.1 GERMANY

8.3.1.2 FRANCE

8.3.1.3 ITALY

8.3.1.3 SPAIN

8.3.1.5 UK

8.3.1.6 REST OF WESTERN EUROPE

8.3.2 EASTERN EUROPE

8.4 ASIA

8.4.1 JAPAN

8.4.2 CHINA

8.4.3 INDIA

8.4.4 AUSTRALIA

8.4.5 REPUBLIC OF KOREA

8.5 REST OF ASIA-PACIFIC

8.6 MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

9.1.1 STRATEGIC PARTNERSHIP

9.1.2 MERGER & ACQUISITION

10 COMPANY PROFILE

10.1 ASTRAZENECA

10.1.1 OVERVIEW

10.1.2 PRODUCT OVERVIEW

10.1.3 FINANCIALS

10.1.4 KEY DEVELOPMENTS

10.2 GLAXOSMITHKLINE

10.2.1 OVERVIEW

10.2.2 PRODUCT OVERVIEW

10.2.3 FINANCIALS

10.2.4 KEY DEVELOPMENTS

10.3 UNIVERSAL HEALTH SERVICES INC

10.3.1 OVERVIEW

10.3.2 PRODUCT OVERVIEW

10.3.3 FINANCIALS

10.3.4 STRATEGY

10.3.5 KEY DEVELOPMENT

10.4 BOEHRINGER INGELHEIM GMBH

10.4.1 OVERVIEW

10.4.2 PRODUCT OVERVIEW

10.4.3 FINANCIALS

10.4.4 KEY DEVELOPMENTS

10.5 ELI LILLY

10.5.1 OVERVIEW

10.5.2 PRODUCT OVERVIEW

10.5.3 FINANCIALS

10.5.4 KEY DEVELOPMENTS

10.6 OTHERS

11 CONCLUSION

11.1 KEY FINDINGS

11.1.1 FROM CEO’S VIEWPOINT

11.1.2 UNMET NEEDS OF THE MARKET

11.2 KEY COMPANIES TO WATCH

11.3 PREDICTION OF INDUSTRY

12 APPENDIX